What is the 13F Pro Quality Score for PROK?

13F Pro ranks PROKIDNEY CORP. (PROK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PROK's current score at https://13fpro.ai/research/PROK (free sign-up required for the full ranking).

Where does 13F Pro source PROK data?

All PROKIDNEY CORP. fundamentals and ownership data come directly from SEC EDGAR. PROKIDNEY CORP. files with the SEC under CIK 1850270. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PROK in?

PROKIDNEY CORP. (PROK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PROK research updated on 13F Pro?

PROK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PROKIDNEY CORP.(PROK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1850270 PROK stock profile & AI dashboard →

13F Pro Quality Score

21.3/100

Rank #2,660 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

72.3/100

Profitability

0.7/100

Balance Sheet

11.2/100

Earnings Quality

30.0/100

Free Cash Flow

0.3/100

Institutional Flow

67.7/100

Revenue Scale

0.5/100

Dilution Risk

0.3/100

PROK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PROKIDNEY CORP. (PROK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PROK at 21.3/100 on a 32-signal composite quality model, placing it at rank #2,660 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.3) and revenue scale (0.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), PROKIDNEY CORP. reports quarterly revenue of $226.0K, net income of $-20.0M, free cash flow of $-45.5M. Top institutional holders of PROK by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, MORGAN STANLEY, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. PROK trades on the Nasdaq exchange and files with the SEC under CIK 1850270. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PROK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PROKIDNEY CORP. directly from SEC EDGAR.

✦

Fun facts about PROKIDNEY CORP.

Quirks, history, and lore behind PROK — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biotech · listed on Nasdaq · focused on regenerative medicine · headquartered in North Carolina.
2
The Numbers
A small-cap company with no product revenue yet — it runs on capital raises and grants while its lead therapy works its way through clinical trials.
3
The History
Founded in the early 2020s and went public via a SPAC merger, riding the wave of investor enthusiasm for cell-therapy platforms targeting hard-to-treat diseases.
4
The Secret
Its core platform uses modified kidney cells — taken from a patient's own body — to potentially treat chronic kidney disease, one of the world's most expensive conditions to manage.
5
The Lore
The company's scientific co-founder is a pioneer in cell therapy for renal disease, and the lead program has drawn attention for its novel autologous cell approach in a disease space with very few good options.
6
The Giveaway
The name is right there in the mission: saving kidneys, one patient's own cells at a time — a biotech whose ticker and name both shout "pro kidney."

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$226.0K

Net Income

Q1 2026

$-20.0M

Free Cash Flow

Q1 2026

$-45.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1075.0% YoY

$893.0KFY 2025

FY22 $0.00FY23 $0.00FY24 $76.0KFY25 $893.0K

Net Income

-12.7% YoY

$-69.0MFY 2025

FY22 —FY23 $-35.5MFY24 $-61.2MFY25 $-69.0M

Operating Income

+10.2% YoY

$-165.0MFY 2025

FY22 $-153.0MFY23 $-151.5MFY24 $-183.7MFY25 $-165.0M

EPS (Diluted)

—FY 2025

FY22 $-0.23FY23 —FY24 —FY25 —

Total Assets

-23.9% YoY

$335.6MFY 2025

FY22 $518.0MFY23 $420.6MFY24 $441.1MFY25 $335.6M

Op. Cash Flow

+4.9% YoY

$-120.1MFY 2025

FY22 $-77.1MFY23 $-90.1MFY24 $-126.4MFY25 $-120.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$893.0K +1075.0%	$76.0K	$0.00	$0.00	—	—
Net Income	$-69.0M -12.7%	$-61.2M -72.5%	$-35.5M	—	—	—
Operating Income	$-165.0M +10.2%	$-183.7M -21.2%	$-151.5M +1.0%	$-153.0M -466.2%	$-27.0M	—
EPS (Diluted)	—	—	—	$-0.23	—	—
Total Assets	$335.6M -23.9%	$441.1M +4.9%	$420.6M -18.8%	$518.0M	—	—
Operating Cash Flow	$-120.1M +4.9%	$-126.4M -40.3%	$-90.1M -16.8%	$-77.1M -206.1%	$-25.2M	—

AI Insight: PROK Financial Trends

Pre-revenue biotech burning $40M+ quarterly with negative equity exceeding $1B; no signs of revenue inflection or cash burn deceleration.

• Revenue remains $0M across all eight quarters; company has not achieved commercial milestone since Q2 2024.

• Operating cash burn averaged $31M/quarter in 2025; Q1 2026 cash outflow accelerated to $42M, worst since Q2 2024.

• Negative equity deteriorated from $972M in Q2 2024 to $1,024M in Q1 2026, signaling ongoing shareholder dilution.

⚠ Operating cash burn spiked Q1 2026 to $42M after three consecutive quarters of improvement; trajectory reversal warrants monitoring.

⚠ Operating losses widened to $45M in Q4 2025 and Q1 2026 after narrowing to $39M in Q3 2025; volatility suggests unpredictable expenses.

AI Insight: PROK Ratio Trends

ProKidney's return on assets deteriorated sharply to -27.4% in Q1 2026, extending a consecutive decline across all nine periods shown.

• ROA worsened from -10.0% in Q2 2024 to -27.4% in Q1 2026, with every quarter posting negative returns.

• Q1 2026 ROA of -27.4% represents the worst reading in the dataset; TTM ROA also at -24.7%.

⚠ Consistent quarter-over-quarter ROA deterioration; no stabilization or recovery evident in the trend.

⚠ Only ROA and D/E reported; OpMargin, NPM, ROE, ROIC data absent—limits visibility into operational and capital efficiency drivers.

Get alerted when PROK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PROKIDNEY CORP. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PROK

SUVRETTA CAPITAL MANAGEMENT, LLC
$22.1M12,341,266 sh
MORGAN STANLEY
$16.0M8,955,967 sh
MILLENNIUM MANAGEMENT LLC
$4.1M2,271,577 sh
Bleichroeder LP
$3.6M2,000,000 sh
Artia Global Partners LP
$3.2M1,806,939 sh
Hennion & Walsh Asset Management, Inc.
$2.9M1,611,693 sh
BlackRock, Inc.
$2.5M1,387,116 sh
RENAISSANCE TECHNOLOGIES LLC
$2.2M1,250,794 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.2M1,230,409 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.1M1,146,937 sh

Fund	Value	Shares
SUVRETTA CAPITAL MANAGEMENT, LLC	$22.1M	12,341,266
MORGAN STANLEY	$16.0M	8,955,967
MILLENNIUM MANAGEMENT LLC	$4.1M	2,271,577
Bleichroeder LP	$3.6M	2,000,000
Artia Global Partners LP	$3.2M	1,806,939
Hennion & Walsh Asset Management, Inc.	$2.9M	1,611,693
BlackRock, Inc.	$2.5M	1,387,116
RENAISSANCE TECHNOLOGIES LLC	$2.2M	1,250,794
GEODE CAPITAL MANAGEMENT, LLC	$2.2M	1,230,409
VANGUARD CAPITAL MANAGEMENT LLC	$2.1M	1,146,937

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PROK on your watchlist

Track score changes the day PROKIDNEY CORP. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PROK a good stock to buy?

13F Pro's AI-powered analysis of PROKIDNEY CORP. (PROK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PROK are available on the PROK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PROK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PROK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PROKIDNEY CORP.'s investment landscape.